Symmetry requirements for effective blocking of pore-forming toxins: Comparative study with α-, β-, and γ-cyclodextrin derivatives

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 7, 2011, Pages 3594-3597

  Yannakopoulou, Konstantina ^a   Jicsinszky, Laszlo ^b   Aggelidou, Crysie ^a   Mourtzis, Nikolaos ^a   Robinson, Tanisha M ^c   Yohannes, Adiamseged ^c   Nestorovich, Ekaterina M ^d,e   Bezrukov, Sergey M ^d   Karginov, Vladimir A ^c  

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^b CycloLab Cyclodextrin Research & Development Laboratory Ltd   (Hungary)

^c Innovative Biologics Inc   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e CATHOLIC UNIVERSITY OF AMERICA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CYCLODEXTRIN DERIVATIVE; ALPHA HEMOLYSIN; ANTHRAX TOXIN; BETA CYCLODEXTRIN DERIVATIVE; GAMMA CYCLODEXTRIN DERIVATIVE; PORE FORMING CYTOTOXIC PROTEIN; STAPHYLOCOCCUS TOXIN;

ARTICLE; BACILLUS ANTHRACIS; CHANNEL GATING; COMPARATIVE STUDY; COMPETITIVE INHIBITION; DRUG CYTOTOXICITY; DRUG STRUCTURE; ENZYME ACTIVITY; IC 50; LIPID MEMBRANE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL;

ALPHA-CYCLODEXTRINS; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; BETA-CYCLODEXTRINS; CELL DEATH; CELL LINE; GAMMA-CYCLODEXTRINS; HEMOLYSIN PROTEINS; MOLECULAR CONFORMATION; STAPHYLOCOCCUS AUREUS;

EID: 79959280680     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01764-10     Document Type: Article

References (12)

1. Backer, M. V., et al. 2007. Inhibition of anthrax protective antigen outside and inside the cell. Antimicrob. Agents Chemother. 51:245-251.
2. Karginov, V. A., et al. 2007. Inhibition of S. aureus α-hemolysin and B. anthracis lethal toxin by β-cyclodextrin derivatives. Bioorg. Med. Chem. 15:5424-5431.
3. Karginov, V. A., et al. 2006. Search for cyclodextrin-based inhibitors of anthrax toxins: synthesis, structural features, and relative activities. Antimicrob. Agents Chemother. 50:3740-3753.
4. Karginov, V. A., et al. 2006. β-Cyclodextrin derivatives that inhibit anthrax lethal toxin. Bioorg. Med. Chem. 14:33-40.
5. Karginov, V. A., E. M. Nestorovich, M. Moayeri, S. H. Leppla, and S. M. Bezrukov. 2005. Blocking anthrax lethal toxin at the protective antigen channel by using structure-inspired drug design. Proc. Natl. Acad. Sci. U. S. A. 102:15075-15080.
6. Kintzer, K. F., et al. 2009. The protective antigen component of anthrax toxin forms functional octameric complexes. J. Mol. Biol. 392:614-629.
7. Moayeri, M., T. M. Robinson, S. H. Leppla, and V. A. Karginov. 2008. In vivo efficacy of β-cyclodextrin derivatives against anthrax lethal toxin. Antimicrob. Agents Chemother. 52:2239-2241.
8. Mourtzis, N., M. Paravatou, I. M. Mavridis, M. L. Roberts, and K. Yannakopoulou. 2008. Synthesis, characterisation, and remarkable biological properties of cyclodextrins bearing guanidinoalkylamino and aminoalkylamino groups on their primary side. Chem. Eur. J. 14:4188-4200.
9. Mourtzis, M., et al. 2007. Synthesis and characterization of per(6-guanidino-6-deoxy)cyclodextrins and studies of their effect on DNA. Org. Biomol. Chem. 5:125-131.
10. Nestorovich, E. M., V. A. Karginov, A. M. Berezhkovskii, and S. M. Bezrukov. 2010. Blockage of anthrax PA63 pore by a multi-charged high-affinity toxin inhibitor. Biophys. J. 99:134-143.
11. Ragle, B. E., V. A. Karginov, and J. B. Wardenburg. 2010. Prevention and treatment of Staphylococcus aureus pneumonia with a β-cyclodextrin derivative. Antimicrob. Agents Chemother. 54:298-304.
12. Szejtli, J. 1998. Introduction and general overview of cyclodextrin chemistry. Chem. Rev. 98:1743-1753.